Welcome
Support Centre
02 September 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A Randomised Trial of CF (Infusional 5-Fluorouracil and Cisplatin) Alone versus CF Plus Concurrent Radiotherapy in Patients with Locally Advanced Pancreatic Carcinoma
ISRCTN ISRCTN54728875
ClinicalTrials.gov identifier
Public title A Randomised Trial of CF (Infusional 5-Fluorouracil and Cisplatin) Alone versus CF Plus Concurrent Radiotherapy in Patients with Locally Advanced Pancreatic Carcinoma
Scientific title
Acronym N/A
Serial number at source PANCRAD
Study hypothesis Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Pancreas cancer
Participants - inclusion criteria 1. Histological evidence of locally advanced or unresectable pancreatic adenocarcinoma
2. Patients evaluable for response must have bidmensionally measurable disease as assessed by Computed Tomography (CT) scans
3. No prior chemotherapy or radiotherapy
4. Life expectancy of >3 months
5. Adequate bone marrow and renal function
6. World Health Organisation (WHO) performance status 0-2 at randomisation
7. No medical contraindications to treatment protocols
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/01/1989
Anticipated end date 11/11/1994
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration
Interventions 1. Regimen A: 5-fluorouracil, continuous infusion for 18 weeks, plus cisplatin repeated every 3 weeks for six cycles.

2. Regimen B: Cisplatin repeated every 3 weeks for four cycles plus 5-fluorouracil, continuous infusion for 12 weeks followed by continuous infusion for a further 6 weeks at a reduced dose. Radiotherapy 50 Gy in twenty-five fractions given over 5 weeks. Radiotherapy to commence on week 13 of chemotherapy.
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Royal Marsden Hospital (UK)
Trial website
Publications
Contact name Dr  -  -
  Address UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
  City/town London
  Zip/Postcode NW1 2DA
  Country United Kingdom
  Tel +44 (0) 20 7670 4723
  Fax +44 (0) 20 7670 4818
  Email register@ctu.mrc.ac.uk
Sponsor The Royal Marsden NHS Foundation Trust (UK)
  Address Downs Road
  City/town Sutton
  Zip/Postcode SM2 5PT
  Country United Kingdom
  Tel +44 (0)20 8661 3156
  Fax +44 (0)20 8643 9414
  Email
Date applied 19/08/2002
Last edited 23/05/2008
Date ISRCTN assigned 19/08/2002
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 ISRCTN unless otherwise stated.


BioMed Central